David Fleming Interview - October
6, 2005
Bill & Melinda Gates Foundation, Seattle
Institutional Links
Resources
- “43
ways to save the world”, June
29, 2005, The Economist Newspaper
- “The
world's richest charity confronts the health of the world's poorest
people”, January 28, 2005, The
Economist Global Agenda
- Labonte
R, Spiegel
J. Setting
global health research priorities.
BMJ. 2003
Apr 5;326(7392):722-3. PMID: 12676822
- T. Pang. Setting
global health research priorities: Ethics should also guide global
health research. BMJ, June 19, 2003;
326(7403): 1399 - 1399.
- M. A. Rab. Setting
global health research priorities: Investments for health research
for developing countries must be increased. BMJ,
June 19, 2003; 326(7403): 1399 - 1399.
- Information
on the communications consultancy that helped make GAVI a success
- Background on the status of GAVI: “Indifference
Toward Vaccinating the Poor” January 21, 2002,
Section A; Column 1; Editorial Desk; Pg. 14, The New York Times
- Fairfield
KM, Fletcher
RH. “Vitamins for chronic disease
prevention in adults: scientific review.” JAMA.
2002 Jun 19;287(23):3116-26. Review. PMID: 12069675 [Stanford]
- Mannar
MG, van
Ameringen M. Food
Nutr Bull. 2003 Dec;24 (4 Suppl):S151-4 “Role
of public-private partnership in micronutrient food fortification.” PMID:
17016958
- Johnson
J. “Stopping Africa's medical brain drain.” BMJ. 2005
Jul 2;331(7507):2-3
Thought Questions
- Who should determine global health priorities and the associated funding?
How should they make these determinations?
- Compare and contrast the global health priorities of the Gates Foundation
with those of the U.S. government.
- Is the type of synergy between public and private funding that Dr.
Fleming describes possible? How?
- Highlight the difference between addressing problems and solving them. What
are the advantages and disadvantages to each?
- Is a business model appropriate in dealing with funding of global health
solutions? Should the Gates Foundation be focusing on technology
and innovations or something else? Why or why not?
- What is attributable benefit? Does it bear any resemblance to
any epidemiological concept you have previously learned about?
- How can philanthropic organizations and governments encourage private
sector, e.g. pharmaceutical companies, to invest in global health?
- What are the advantages and disadvantages of micronutrient fortification
of foods? What is biofortification? Does it resolve some
of these associated issues?
- Give an example of an epidemiological shift. Explain how it was
detected and how it was addressed. Why is disease surveillance
necessary? How can it be implemented in resource poor settings?
- What
are the four things necessary to deliver interventions to those who need
them? When is modeling necessary and why? What are the limitations
of using models to analyze health conditions? Why is the current
system inefficient? What are possible solutions?
|
|
|
